SynlogicSYBX
About: Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 17 [Q1] → 17 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.2% less ownership
Funds ownership: 59.46% [Q1] → 59.26% (-0.2%) [Q2]
16% less capital invested
Capital invested by funds: $12.4M [Q1] → $10.4M (-$1.99M) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for SYBX.
